Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) Debt to Equity (2016 - 2025)

Altimmune (ALT) has disclosed Debt to Equity for 13 consecutive years, with $0.15 as the latest value for Q4 2025.

  • Quarterly Debt to Equity changed N/A to $0.15 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.15 through Dec 2025, changed N/A year-over-year, with the annual reading at $0.15 for FY2025, N/A changed from the prior year.
  • Debt to Equity for Q4 2025 was $0.15 at Altimmune, up from $0.08 in the prior quarter.
  • The five-year high for Debt to Equity was $0.15 in Q4 2025, with the low at $0.01 in Q2 2021.
  • Average Debt to Equity over 4 years is $0.04, with a median of $0.03 recorded in 2023.
  • Peak annual rise in Debt to Equity hit 368.0% in 2021, while the deepest fall reached 83.68% in 2021.
  • Over 4 years, Debt to Equity stood at $0.04 in 2021, then crashed by 34.74% to $0.02 in 2022, then rose by 15.78% to $0.03 in 2023, then soared by 432.62% to $0.15 in 2025.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.15, $0.08, and $0.09 for Q4 2025, Q3 2025, and Q2 2025 respectively.